Retrospective descriptive study of adult tuberculosis in Wuhan, China

International Journal of Tuberculosis and Lung Disease

Volumn 8, Issue 6, 2004, Pages 730-736

  Chamla, D D ^a   Nie, S ^a   Duan, Q ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Retreatment TB; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADULT; AGE; ARTICLE; BCG VACCINATION; CHINA; EXTRAPULMONARY TUBERCULOSIS; FEMALE; GENDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; RETREATMENT; RETROSPECTIVE STUDY; SCREENING; SHORT COURSE THERAPY; SPUTUM CULTURE; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; CHINA; COHORT STUDIES; DIRECTLY OBSERVED THERAPY; FEMALE; HOSPITALS, SPECIAL; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RECURRENCE; RETROSPECTIVE STUDIES; SEX FACTORS; SPUTUM; TUBERCULOSIS, PULMONARY;

EID: 2942545975     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. World Health Organization. Global Tuberculosis Control: surveillance, planning, financing. WHO Report 2002. WHO/CDS/TB/2002.295. Geneva, Switzerland: WHO, 2002.
2. Gazzard B. Tuberculosis, HIV and the developing world. Clin Med 2001; 1: 62-68.
3. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization, 1991. Bull World Health Organ 2001; 79: 71-75.
4. World Health Organization. Report of the ministerial conference on TB and sustainable development, Amsterdam. WHO/CDS/STB/2000.6. Geneva, Switzerland: WHO, 2000.
5. Dye C, Gammet G P, Sleeman K, Williams B G. Prospects for worldwide TB control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet 1998; 352: 1886-1891.
6. World Health Organization. Overcoming antimicrobial resistance. WHO/CDS/2000.2. Geneva, Switzerland: WHO, 2000.
7. Ravligione M C, Snider D, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of worldwide epidemic. JAMA 1995; 273: 220-226.
8. World Health Organization. Anti-tuberculosis resistance in the world. Report no. 2: Prevalence and Trend. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. WHO/CDS/TB/2000.278. Geneva, Switzerland: WHO, 2000.
9. Duanmu H. Report on fourth national epidemiological sampling survey of tuberculosis. Zhonghua Jie He He Huxi Zazhi 2002; 25: 3-7.
10. National technical group of epidemiological survey for tuberculosis. Nationwide random survey on the epidemiology of pulmonary tuberculosis in China. Zhonghua Jie He He Huxi Zazhi 1990; 13: 67-70.
11. Cao J P, Zhang L Y, Zhu J Q, Chin D P. Two years follow-up of directly-observed intermittent regimens for smear positive pulmonary tuberculosis in China. Int J Tuberc Lung Dis 1998; 2: 360-364.
12. Zhang L X, Tu D H, Enarson D A. The impact of directly-observed treatment on epidemiology of tuberculosis in Beijing. Int J Tuberc Lung Dis 2000; 4: 904-910.
13. Shanghai Pulmonary Tuberculosis Epidemiological Research Group. A three year retrospective cohort study on pulmonary tuberculosis in Shanghai. Zhonghua Jie He He Huxi Zazhi 1995; 18: 309-320.
14. Liu X R. A relapse and its potential causes in pulmonary tuberculosis. Zhonghua Jie He He Huxi Zazhi 1993; 16: 66-72.
15. Wang L X, Liu S G, Wang X J. Study on geographic distribution of smear-positive pulmonary tuberculosis with trend-surface analysis. Zhonghua Liu Xing Bing Xue Za Zhi 1995; 16: 274-276.
16. Peng J. Symptomatic survey on pulmonary tuberculosis in Shanghai rural areas. Zhonghua Jie He He Huxi Zazhi 1993; 16: 83-84, 123.
17. Narain J P, Raviglione M C, Kochi A. HIV-associated tuberculosis in developing countries; epidemiology and strategies for prevention. Tubercle Lung Dis 1992; 73: 311-321.
18. Espinal M A, Kim S J, Suarez P G, et al. Standard short-course chemotherapy for treatment of drug-resistant tuberculosis: outcomes of 6 countries. JAMA 2000; 283: 2537-2545.
19. Dye C, Fengzeng Z, Scheele S, Williams B. Evaluating the impact of tuberculosis control: number of deaths prevented by short course chemotherapy in China. Int J Epidemiol 2000; 29: 558-564.
20. Liu J, Xiong C, Wang X, et al. Analysis on effects of TB control project loaned by World Bank in Hubei. Zhongguo Fang Lao Zazhi 2001; 23: 91-94.
21. Qian Y F. Evaluation of BCG vaccination programme based on results of the Third Nationwide Tuberculosis Survey. Zhonghua Jie He He Hu Xi Za Zhi 1994; 17: 281-285.
22. Yang C, Yang S, Li M. The analysis of factors affecting seek medical advice of suspected pulmonary TB cases. Zhongguo Fang Lao Zazhi 2001; 23: 106-108.
23. Davies P D O. Clinical tuberculosis. London, UK: Chapman and Hall, 1994.
24. Hou S, Xiao A, Li G, et al. Analysis of factors affecting initial/retreated case-finding ratio of tuberculosis cases in Hubei province. Zhongguo Fang Lao Za Zhi 1999; 21: 132-134.
25. Zhung Y, et al. A surveillance study on epidemiology of tuberculosis in urban area of Wuhan. Zhong Hua Jie He He Huxi Zazhi 1987; 10: 99-101.
26. Wuhan TB Control Centre. Annual report on Tuberculosis in Wuhan city 2001. Wuhan, China: Wuhan TB Control Centre, 2001.
27. Nakata K, Honda Y, Tanaka N, Weiden M, Keicho N. Tuberculosis in patients with acquired immune deficiency syndrome. Kekkaku 2000; 75: 547-556.
28. Harries A D, Hargreaves N J, Kwanjana J H, Salaniponi F M. Relapse and recurrent tuberculosis in the context of a national tuberculosis control programme. Trans R Soc Trop Med Hyg 2000; 94: 247-249.
29. Harries A D, Hargreaves N J, Kwanjana J H, Salaniponi F M. Recurrent tuberculosis: definitions and treatment regimens. Int J Tuberc Lung Dis 1999; 3: 851-854.
30. van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999; 341: 1174-1179.
31. Hnizdo E, Singh T, Churchyard G. Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment. Thorax 2000; 55: 32-38.
32. Anonymous. First-line chemotherapy in the retreatment of bacteriological relapses of pulmonary tuberculosis following a shortcourse regimen. Lancet 1976; 1: 162-163.
33. White V L, Moore-Gillon J. Resource implications of patients with multidrug resistant tuberculosis. Thorax 2000; 55: 962-963.
34. Banda H, Kang'ombe C, Harries A D, et al. Mortality rates and recurrent rates of tuberculosis in patients with smear negative pulmonary tuberculosis and tuberculous pleural effusion who have completed treatment. Int J Tuberc Lung Dis 2000; 4: 968-974.
35. Kopanoff D E, Snider D E Jr, Johnson M. Recurrent tuberculosis: why do patients develop disease again? A United States Public Health cooperative survey. Am J Public Health 1998; 78: 30-33.
36. Rajeswari R, Chandrasekaran V, Suhadev M, Sivasubramaniam S, Sudha G, Renu G. Factors associated with patient and health system delays in the diagnosis of tuberculosis in South India. Int J Tuberc Lung Dis 2002; 6: 789-795.
37. Wandwalo E R, Morkve O. Delay in tuberculosis case-finding and treatment in Mwanza, Tanzania. Int J Tuberc Lung Dis 2000; 4: 133-138.
38. Volmink J, Marchaba P, Gomer P. Direct observed therapy and treatment adherence. Lancet 2000; 355: 1345-1350.
39. Marciniuk D D, McNa B D. Detection of PTB in patients with a normal chest X-ray. Chest 1999; 115: 445-452.
40. Van Deun A, Portaels F. Limitations and requirements for quality control of sputum smear microscopy. Int J Tuberc Lung Dis 1998; 2: 756-765.
41. Arbelaez M P, Nelson K E, Munoz A, BCG vaccine effectiveness in preventing tuberculosis and its interaction with human immunodeficiency virus infection. Int J Epidemiol 2000; 29: 1085-1091.
42. Corrah T, Byass P, Jaffar S, et al. Prior BCG vaccination improves survival of Gambian patients treated for pulmonary tuberculosis. Trop Med Int Health 2000; 5: 413-417.
43. TB Research Centre, Chennai. Low rate of emergence of drug resistance in sputum positive patients treated with short course chemotherapy. Int J Tuberc Lung Dis 2001; 5: 40-45.